Skip to content
Close
ESMO-TAT-2026-Onsite-background

esmo targeted anticancer
therapies (tat) 2026

16 - 18 March 2026
Paris, France
Download the prospectus

ABOUT ESMO TARGETED ANTICANCER THERAPIES (TAT) CONGRESS 2026

The journey of innovation in cancer treatment begins with early drug development. ESMO TAT serves as a dynamic, multi-stakeholder forum, uniting researchers, industry leaders, investors, regulators, and patient advocates under one roof to accelerate the delivery of life-changing anticancer therapies to patients.

Learning objectives

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
  • Ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
  • Reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
  • Culpa qui officia deserunt mollit anim id est laborum.

Scientific Co-Chairs

 

Elena Garralda
Elena Garralda Barcelona, Spain
Carlos Gomez-Roca
Carlos Gomez-Roca Toulouse, France
Cristian Massacesi
Cristian Massacesi New York, United States

PROGRAMME HIGHLIGHTS

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. Lorem ipsum dolor sit amet, consetetur sadipscing elitr. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod 

 

Background for banner_ Download the full programme

Download the full programme

Download the prospectus

CONGRESS FACTS

PARTICIPANTS

594

Countries & Territories

57

Oncology Clinicians

58.7%

Abstracts presented

121

Programme Speakers

66

Image 1
Image 2
Image 3
ESMO-TAT-2026-2

Download the prospectus to find out about sponsorship and funding opportunities

Download
ESMO-TAT-2026

Download the full 2025 post-event report

Download

ESMO TARGETED ANTICANCER THERAPIES (TAT) 2025 SUPPORTERS

PLATINUM SPONSORS

AstraZeneca Novartis

 

GOLD SPONSORS

Bristol Myers logo-roche

 

SILVER SPONSORS

Bayer

 

SUPPORTERS

Amgen logo-pfizer

 

EXHIBITORS

MCE Novartis-1 Resilience

 

EDUCATIONAL GRANTS

Johnson&Johnson Linstitut Servier MSD

 

Contact us for further details or information on ESMO Targeted Anticancer Therapies (TAT) 2026